GLIDE study

  • Research type

    Research Study

  • Full title

    NIHR Imperial BRC Research fellowship - Glycaemic Index, extended bolusing and diabetes education in insulin pump therapy (GLIDE study)

  • IRAS ID

    200737

  • Contact name

    Nick Oliver

  • Contact email

    nick.oliver@imperial.ac.uk

  • Sponsor organisation

    Imperial College London

  • Duration of Study in the UK

    0 years, 3 months, 22 days

  • Research summary

    People with Type 1 Diabetes (T1DM) have to inject insulin under the skin to mimic non-diabetic insulin secretion. One treatment option for people with T1DM is Continuous subcutaneous insulin infusion (CSII) therapy, which delivers rapid acting insulin continuously from a small, portable, battery-operated pump about the size of a small pager. Insulin pumps are better able to match the natural physiology of the body and can extend insulin bolus administration to match slowly digested foods without a mismatch of food and insulin. This is important as not all carbohydrate is digested at the same rate, making diabetes self-management with differing foods challenging. The majority of people on CSII use insulin doses delivered over several minutes for most meals. However, individuals will often avoid specific foods or meals because of past experiences of high or low glucose levels after consuming these foods. The advice currently given to insulin pump users on how to manage slowly digested food is very varied. There is no published evidence on whether educating patients on glycaemic index, and changing the insulin delivered with food to better match the duration of food absorption can affect blood glucose control, quality of life or treatment satisfaction.
    This study aims to investigate people’s current experiences of different foods and different insulin patterns using a patient focus group. Then the study will investigate how a half day education programme to enable self-management, created from information we have from published and unpublished evidence, affects glucose control, quality of life and treatment satisfaction.

  • REC name

    London - Fulham Research Ethics Committee

  • REC reference

    16/LO/0640

  • Date of REC Opinion

    6 May 2016

  • REC opinion

    Further Information Favourable Opinion